The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...
A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...
R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.
The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.
SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...
The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...
The agency's decision not to approve this formulation was based on issues identified during a pre-approval inspection at a manufacturing facility, the firm said.
The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback